These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16759055)

  • 21. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
    Weiss J; Weis N; Ketabi-Kiyanvash N; Storch CH; Haefeli WE
    Eur J Pharmacol; 2008 Jan; 579(1-3):104-9. PubMed ID: 18037401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate.
    De Clercq E
    Expert Opin Pharmacother; 2009 Dec; 10(17):2935-7. PubMed ID: 19929712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
    Andreatta K; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2013 Apr; 62(4):367-74. PubMed ID: 23187937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
    AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracellular pharmacology of emtricitabine and tenofovir.
    Stevens RC; Blum MR; Rousseau FS; Kearney BP
    Clin Infect Dis; 2004 Sep; 39(6):877-8; author reply 878-9. PubMed ID: 15472830
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
    Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
    Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
    Margot NA; Waters JM; Miller MD
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4087-95. PubMed ID: 16982781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
    von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2008 Apr; 46(8):1299-309. PubMed ID: 18444871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
    Jansen RS; Rosing H; Kromdijk W; ter Heine R; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Mar; 878(7-8):621-7. PubMed ID: 20122883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
    Pruvost A; Negredo E; Benech H; Theodoro F; Puig J; Grau E; García E; Moltó J; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2005 May; 49(5):1907-14. PubMed ID: 15855513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.
    Schinazi RF; Bassit L; Clayton MM; Sun B; Kohler JJ; Obikhod A; Arzumanyan A; Feitelson MA
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6186-91. PubMed ID: 22985879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4.
    Clemente MI; Alvarez S; Serramía MJ; Turriziani O; Genebat M; Leal M; Fresno M; Muñoz-Fernández MA
    Antivir Ther; 2009; 14(8):1101-11. PubMed ID: 20032540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
    Cihlar T; Ray AS; Laflamme G; Vela JE; Tong L; Fuller MD; Roy A; Rhodes GR
    Antivir Ther; 2007; 12(2):267-72. PubMed ID: 17503669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).
    Férir G; Vermeire K; Huskens D; Balzarini J; Van Damme EJ; Kehr JC; Dittmann E; Swanson MD; Markovitz DM; Schols D
    Antiviral Res; 2011 Jun; 90(3):200-4. PubMed ID: 21501631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.
    Margot NA; Johnson A; Miller MD; Callebaut C
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5917-24. PubMed ID: 26149983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
    Miller MD; Margot NA; Hertogs K; Larder B; Miller V
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1025-8. PubMed ID: 11562951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
    Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
    J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.